Novel Personalized Management Approaches in Rheumatoid Arthritis

Title:

Novel Personalized Management Approaches in Rheumatoid Arthritis

Topic: Rheumatology
Relevant Terms: Rheumatoid Arthritis
Primary Audience: Rheumatologists
Launch Date: 16-May-17
Credits: 0.5 AMA PRA Category 1 Credit
Expiration Date: 16-May-18
Curriculum Name: Tailoring Approaches to Management in Patients with RA: What’s New?

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Utilize appropriate risk-assessment and monitoring tools for RA patients to assess disease activity and direct individualized management decisions
  2. Integrate new and emerging IL-6 directed therapies in rheumatoid arthritis for individualized treatment plans based on safety and efficacy data, patient selection data, and the rationale for targeting the IL-6 pathway
  3. Incorporate strategies for a collaborative approach to RA care that includes a multidisciplinary team of health professionals and includes patient preferences into treatment selection

    Faculty

    Vibeke Strand, MD, MACR, FACP
    Adjunct Clinical Professor
    Division of Immunology/Rheumatology
    Stanford University School of Medicine
    Stanford, CA
    Martin Jan Bergman, MD, FACR, FACP, FCPP
    Clinical Associate Professor of Medicine
    Drexel University School of Medicine
    Philadelphia, PA
    Eric M. Ruderman, MD
    Professor of Medicine, Department of Rheumatology
    Northwestern University
    Chicago, IL
    PHYSICIAN CONTINUING MEDICAL EDUCATION
    Accreditation Statement
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RMEI Medical Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
     
    Credit Designation
    The University of Cincinnati designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    Joint Providership Statement
    This CME activity is jointly provided by the University of Cincinnati and RMEI Medical Education, LLC.
     
    COMMERCIAL SUPPORT
    This activity is supported by an independent educational grant from Genzyme, a Sanofi Company and Regeneron Pharmaceuticals.   
     
    DISCLOSURE OF CONFLICTS OF INTEREST
    According to the disclosure policy of the University of Cincinnati College of Medicine, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. Disclosure will be made at the time of activity.
     
    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
    • Vibeke Strand, MD, MACR, FACP, has affiliations with AbbVie, Alder, Amgen Inc., Anthera, Asana, AstraZeneca, aTyr, Bayer, Biogen ldec, Boehringer Ingelheim, BMS, Carbylan, Celgene, Celltrion, CORRONA, Crescendo/Myriad Genetics, EMD Serono, Eupraxia, Genentech/Roche, GlaxoSmithKline, Horizon, Iroko, Janssen, Jazz Pharmaceuticals, Kezar, Kypha, Lilly, Merck, Novartis, Pfizer, Protagen, Regeneron, Samsung, Samumed, Sandoz, SKK, UCB, and XTL (Consulting Fees); and AbbVie, Amgen, Anthera, AstraZeneca, Bayer, Biogen ldec, BMS, Carbylan, Celltrion, Crescendo, EMD Serono, Genentech/Roche, GSK, Horizon, Iroko, Janssen, Jazz, Lilly, Merck, Novartis, Pfizer, Protagen, Regeneron, Samsung, Sandoz, Sanofi, and UCB (Advisory Boards)
    • Martin Jan Bergman, MD, FACR, FACP, FCPP, has affiliations with AbbVie, Amgen, Celgene, Genentech, Janssen, Novartis, and Pfizer (Advisory Boards); Johnson & Johnson and Pfizer (Fees for Non-CME/CE Services Received Directly from a Commercial Interest or Their Agents); AbbVie and Celgene (Speaker’s Bureau); and Spouse: Amgen (Consulting Fees)
    • Eric M. Ruderman, MD, has affiliations with BMS, Lilly (Advisory Boards); AbbVie, Amgen, Genentech/Roche, GSK, Lilly, Novartis, Pfizer, and Vertex (Consulting Fees); and Pfizer (Contracted Research/Grants).
    University of Cincinnati
    • Susan P. Tyler, MEd, CMP, CHCP, CME Director, has no affiliations with commercial interests relative to the content to disclose.
    • Rick E. Ricer, MD, Professor Emeritus, CME Physician Reviewer, has no affiliations with commercial interests relative to the content to disclose.
    • Deborah Cole, BS, Program Coordinator, has no affiliations with commercial interests relative to the content to disclose.
    RMEI Medical Education, LLC
    • Sy Schlager, MD, PhD, has no affiliations with commercial interests relative to the content to disclose. 
    • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests relative to the content to disclose.
    • Tania Dickson, PhD, has no affiliations with commercial interests relative to the content to disclose.
    • Leslie Treff, JD, has no affiliations with commercial interests relative to the content to disclose.
    DISCLAIMER
    The opinions expressed during the enduring activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati. The information is presented for the purpose of advancing the attendees’ professional development.
     
    DISCLOSURE OF UNLABELED USE
    Faculty members are required to inform the audience when they are discussing off label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.
      
    Estimated time to complete: 0.5 hours
    Medium: Internet
     
    FEE INFORMATION
    There is no fee for this educational activity.
     
    HOW TO RECEIVE CREDIT
    By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to .5 AMA PRA Category 1 Credits™. A statement of credit will be available to print from your user history page. Users must:
     
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity post-test and evaluation.
    Physicians, nurse practitioners, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. You must score 70% or higher on the post-test to receive credit for this activity. Participants have 3 attempts to successfully pass the post-test. 
     
    CONTACT INFORMATION
     
    Accreditation Support:
    Please contact the University of Cincinnati Continuing Medical Education Department at uccme@uc.edu or call 513-558-7277.

    Technical Support:
    For any technical issues or issues with your CME Certificate, please visit: support center /cms/support-center
     
    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above
     
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above.